New and Emerging Agents in the Treatment of Diffuse Large B-Cell Lymphoma
In this segment, “New and Emerging Agents in the Treatment of Diffuse Large B-Cell Lymphoma”, Laurie Sehn, MD, MPH, and Gilles Salles, MD, discuss new data and future directions in DLBCL therapy.
While it is an exciting time in the management of DLBCL, the amount of emerging data and numerous approvals in recent years have created more questions regarding the optimal use and sequencing of these new agents. Antibody drug conjugates, CAR T-cell therapy, and bispecific antibodies have shown impressive potential in pretreated patients. Looking to the future, these novel options may move toward frontline therapy, further changing the DLBCL treatment paradigm.